Guided Therapeutics Valuation
| GTHP Stock | USD 0.19 0.03 18.75% |
Guided Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Guided Therapeutics from evaluating the firm fundamentals such as Return On Asset of -0.63, shares owned by insiders of 39.69 %, and Operating Margin of (38.63) % as well as inspecting its technical indicators and probability of bankruptcy. . In general, most investors encourage buying undervalued assets and selling overvalued assets since, at some point, asset prices and their ongoing real values will come together.
Overvalued
Today
Please note that Guided Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Guided Therapeutics is based on 3 months time horizon. Increasing Guided Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Guided otc stock is determined by what a typical buyer is willing to pay for full or partial control of Guided Therapeutics. Since Guided Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Guided OTC Stock. However, Guided Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.19 | Real 0.15 | Hype 0.19 |
The intrinsic value of Guided Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Guided Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Guided Therapeutics helps investors to forecast how Guided otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Guided Therapeutics more accurately as focusing exclusively on Guided Therapeutics' fundamentals will not take into account other important factors: Guided Therapeutics Total Value Analysis
Guided Therapeutics is currently forecasted to have valuation of 19.66 M with market capitalization of 12.77 M, debt of 1.43 M, and cash on hands of 446 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Guided Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
19.66 M | 12.77 M | 1.43 M | 446 K |
Guided Therapeutics Investor Information
About 40.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.19. Guided Therapeutics last dividend was issued on the 29th of March 2019. The entity had 1:800 split on the 29th of March 2019. Based on the key indicators related to Guided Therapeutics' liquidity, profitability, solvency, and operating efficiency, Guided Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Guided Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Guided Therapeutics has an asset utilization ratio of 3.97 percent. This connotes that the OTC Stock is making $0.0397 for each dollar of assets. An increasing asset utilization means that Guided Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Guided Therapeutics Ownership Allocation
Guided Therapeutics has a total of 48.58 Million outstanding shares. Guided Therapeutics secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Guided Therapeutics Profitability Analysis
The company reported the previous year's revenue of 81 K. Net Loss for the year was (2.07 M) with profit before overhead, payroll, taxes, and interest of 20 K.About Guided Therapeutics Valuation
The otc valuation mechanism determines Guided Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Guided Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Guided Therapeutics. We calculate exposure to Guided Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Guided Therapeutics's related companies.Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia. Guided Therapeutics operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 5 people.
8 Steps to conduct Guided Therapeutics' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Guided Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Guided Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Guided Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Guided Therapeutics' revenue streams: Identify Guided Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Guided Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Guided Therapeutics' growth potential: Evaluate Guided Therapeutics' management, business model, and growth potential.
- Determine Guided Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Guided Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Guided Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Guided Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 13.7 M | |
| Retained Earnings | -142.4 M |
Additional Tools for Guided OTC Stock Analysis
When running Guided Therapeutics' price analysis, check to measure Guided Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guided Therapeutics is operating at the current time. Most of Guided Therapeutics' value examination focuses on studying past and present price action to predict the probability of Guided Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guided Therapeutics' price. Additionally, you may evaluate how the addition of Guided Therapeutics to your portfolios can decrease your overall portfolio volatility.